Sun Pharma Advanced Research Company
Sun Pharma Advanced Research (SPARC) reported 2.62% growth in the Sep-20 quarter top line revenues at Rs17.64cr on a consolidated basis. SPARC is in the sole business of clinical trials and research and that being a long gestation investment requires substantial upfront losses to be taken. While the company is trying to raise funds in the market to meet the funding gap, it is temporarily being supported by its parent company, Sun Pharma.


While the pharma and API business have benefited from the COVID pandemic, the research business has not gained significantly.


Financial highlights for Sep-20 compared yoy and sequentially









Sun Pharma Advanced Research

Rs in Crore

Sep-20

Sep-19

YOY

Jun-20

QOQ

Revenues

17.64

17.19

2.62%

185.45

-90.49%

Profit After Tax (PAT)

-83.49

-63.16

Not Relevant

56.69

Not Relevant

Diluted EPS (Rs)

₹ -3.19

₹ -2.41

₹ 2.16

PAT Margins

-473.30%

-367.42%

30.57%

 
 

Related Story



Related Tags:







Source link
#SPARC #net #loss #widens #Rs8349cr #higher #clinical #trial #costs

Leave a comment

Your email address will not be published. Required fields are marked *